MSCI Biotech Advance Indexes

The health-care sector, particularly the biotech space, is encountering both opportunities and challenges in the post-pandemic world. Primary among these challenges is a looming patent cliff, created by many leading drugs losing their patent protection between 2025 and 2035. This loss is anticipated to cause a substantial decline in the worldwide sales of major drugs, paving the way for generics and biosimilars, a nearly identical copy of the original product manufactured by a different company. It also presents opportunities for companies to fuel research, accelerate drug development pipelines and bring innovative treatments to market faster.

The MSCI Biotech Advance Indexes, composed of companies at the forefront of innovation in drug development and therapeutics, are designed to reflect the changing biotech space over the coming years.

Historical sales impact of major drugs going off patent

We show the annual reported worldwide sales of major products expiring in each year from 1986 through 2023 and forecasted worldwide sales through 2030. Eligible products are based on new chemical or biological entities with over USD 10 billion in 2023 worldwide sales. Source: Evaluate Pharma